HIV & AIDS

UG module Dr. Hala Altarawneh






Human Immunodeficiency Virus



A virus that attacks the body's **immune system**

HIV


- Family: Retroviridae
- Genus: Lentivirus
- Species:
 - HIV-1: most common species worldwide
 - HIV-2: restricted to West Africa
- Structure: icosahedral with a conical capsid and a spiked envelope.
- Genome: it carries single-stranded RNA as its genetic material.



HIV: Routes of Transmission

- Sexual: responsible for $\sim 80\%$ of infections worldwide.
- Parenteral transmission:
 - Needle sharing, Needlestick injuries
 - Infectious blood on mucous membranes
 - Blood transfusions.
- Vertical transmission: from mother to child during childbirth or through breastfeeding after birth.

HIV replication cycle



HIV: HIV replication cycle

- 1. HIV enters the body (e.g., via mucosal lesions), then attaches to the CD4 receptor on host cells with its gp120 glycoprotein (Binding)
 - Cells that have CD4 receptors: T lymphocytes (e.g., T helper cells), macrophages, monocytes, dendritic cells.
- 2. Viral envelope fuses with host cell, capsid enters the cell. (Fusion)
 - For fusion, CD4 receptor and a coreceptor (CCR5 in macrophages) must be present.
- 3. A virion's RNA is transcribed into dsDNA by viral reverse transcriptase. (Reverse transcription)
- 4. Viral DNA is transported across the nucleus and integrated into the host DNA by viral integrase. (Integration)
- 5. Viral DNA is transcribed, and multiple copies of new HIV RNA form and are transported to the cytoplasm \rightarrow new HIV RNA becomes the genome of a new

HIV: HIV replication cycle

- 6. New viral RNA + proteins + enzymes move to the cell surface and form a noninfectious particle (Assembly)
- 7. Particle (viral RNA + proteins) eventually buds out of the host cell with the immature HIV. (Budding)
- 8. Viral protein protease then cleaves newly synthesized polyproteins, producing a **mature HIV**.


HIV: Progression of Disease- Acute Phase

- 1. HIV infects and destroys CD4+ T cells, macrophages, and dendritic cells in mucosal tissues.
- 2. Dissemination and replication in lymph nodes occur, then proceed to other lymphoid compartments (more CD4+ target cells) → viremia.
- 3. CD8+ cytolytic T lymphocytes (CTLs) are activated, and this immune response produces a partial control of viral replication.
- 4. Acute retroviral syndrome:
 - 1. Clinical presentation of self-limited acute viral illness
 - 2. Associated with millions of copies of HIV RNA/mL of plasma
 - 3. High likelihood of transmission during this period

HIV: Clinical features- Acute HIV infection

- In early HIV infection, patients are often asymptomatic.
- Fever, Fatigue, headache
- Myalgia and arthralgia
- Generalized nontender lymphadenopathy, Generalized rash
- Gastrointestinal symptoms (nausea, diarrhoea, weight loss)
- Oropharyngeal symptoms (sore throat, ulcerations, painful swallowing)

HIV: Clinical features- Acute HIV infection



HIV: Progression of Disease- Chronic phase

- Low-level replication of virus in lymphoid tissues and slow progressive T cell depletion
- Sustained replication generates mutation, contributing to viral escape from the control of CD8+ CTLs.

HIV: Clinical features- Chronic HIV infection

• Chronic infection (clinical latency): Few or no clinical manifestations of infection

HIV: Progression of Disease- AIDS

<u>Acquired Immune Deficiency Syndrome (AIDS)</u>

- Increasing loss of CD4+ lymphocytes → impairs immune function → facilitates opportunistic infections and development of malignancies (AIDS).
- These secondary diseases are usually the cause of death in individuals with HIV.



HIV: Clinical features- AIDS

- AIDS (also known as advanced HIV) is defined as the development of an AIDS-defining condition or a CD4 count of < 200 cells/µL in HIV-infected patients.
- AIDS-defining conditions are a set of potentially life-threatening conditions that indicate the progression of HIV infection to AIDS.

HIV: Clinical features- AIDS

- As the CD4 count declines, the immune system is weakened and many pathological processes may occur, such as:
 - Development of malignancies e.g., non-Hodgkin lymphomas
 - Rapid spread of opportunistic and non-opportunistic bacterial and fungal infections (e.g., coccidioidomycosis, pneumocystis pneumonia, mycobacterial infections)
 - Reactivation of latent infections (e.g., tuberculosis, herpes simplex infections, shingles).

CLINICAL MANIFESTATION OF AIDS

IMMUNOLOGIC:

- Low white cell counts CDT₄ count < 200/mm³
- Opportunistic Infections
- Lymphadenopathy
- Fatigue

INTEGUMENTARY:

- Poor Wound Healing
- Skin Lesions
- Night Sweats

RESPIRATORY:

- Cough
- 50B

GASTROINTESTINAL:

- Diarrhea
- Weight Loss
- Nausea/Vomiting

CENTRAL NERVOUS SYSTEM:

- Confusion
- Dementia
- Headache
- Visual Changes
- Personality Changes
- Pain
- Seizures



OPPORTUNISTIC INFECTIONS:

Protozoal Infections

- Pneumocystis Carinii Pneumonia
- Toxoplasmosis (Encephalitis)
- Cryptosporidiosis (G1)

Fungal Infections

• Candidiasis - Stomatitis Esophagitis Vaginal

Bacterial Infections

- Mycobacterium Complex
- Tuberculosis

Viral Infections

- Cytomegalovirus
- Herpes Simplex Virus
- Varicella-Zoster Virus


MALIGNANCIES:

- Kaposi's Sarcoma
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- Invasive Cervical Carcinoma

AIDS DEMENTIA COMPLEX:

Cognitive, Motor and Behavioral Impairments in 70% AIDS Clients

HIV: Progression to chronic immunodeficiency



HIV: Diagnosis

- Serological assays
 - HIV antigen alone: detects HIV p24 antigen
 - HIV antibody assays: Detect IgM and IgG antibodies

• Virological testing:

- Virological tests are most commonly used for screening infants and confirmation of disease in both infants and adults.
- Can detect HIV-1 RNA and/or DNA through nucleic acid testing (NAT).
- Can measure the amount of viral RNA in the blood and detect HIV infection earlier than antibody/antigen-based tests


HIV: Management

- There is **no cure for HIV**, but all individuals with HIV infection should begin **antiretroviral therapy** (ART) as soon as possible.
- Goals:
 - Suppress plasma HIV RNA.
 - Improve immunologic function.
 - Reduce HIV-associated complications and prolong survival.
 - Reduce HIV transmission.
- Once initiated, treatment is indefinite.
- Establish regular monitoring to assess treatment response.

HIV: Management- Antiretroviral Drugs

- Th Entry inhibitors:
 - CCR5 antagonist: Inhibits the attachment of the virus to the CD4 cell by blocking binding of gp120
 - Attachment inhibitor: Binds gp120, preventing viral attachment
- Reverse transcriptase inhibitors interfere with the translation of viral RNA into DNA
- Integrase strand transfer inhibitors: Prevent the insertion of the viral genome into the host DNA
- Antiretroviral drugs are combined to prevent resistance

HIV replication cycle



HIV: Management

- If CD4 count is < 200, start prophylaxis for opportunistic infections.
- Treat AIDS-defining condition if present.
- Immunizations: in addition to routine vaccinations, the following vaccines should be prioritized in this population:
 - Hepatitis A&B
 - Human papilloma virus vaccine
 - Influenza vaccine (annually)
 - Meningococcal and Pneumococcal vaccine
 - Herpes zoster, and COVID vaccine.

HIV: Prognosis

- Untreated HIV leads to death on average 8–10 years after infection.
- Progression varies among individuals: Some patients may die within a few years while others can remain asymptomatic for decades.
- The average life expectancy of HIV-infected individuals who receive adequate antiretroviral treatment is approaching that of noninfected individuals of the same age.

Thank you